Publications by authors named "Alan Barge"

Claim this Profile
C
Correction: Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms.
Aditi Jain, Alan Barge, Christopher N Parris

Oncogene· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms.
Aditi Jain, Alan Barge, Christopher N Parris

Oncogene· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers.
Aflah Roohullah, Adam Cooper, Anna J Lomax, Jennifer Aung, Alan Barge

Invest New Drugs· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors.
Patricia M LoRusso, Shirish M Gadgeel, Antoinette Wozniak, Alan J Barge, Helen K Jones

Invest New Drugs· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model.
Claudius Conrad, Ivan Ischenko, Gudrun Köhl, Ulrich Wiegand, Markus Guba, Alan Barge

Anticancer Drugs· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing randomized phase II trials assessing tumor progression.
Andrew Stone, Catherine Wheeler, Kevin Carroll, Alan Barge

Contemp Clin Trials· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving the design of phase II trials of cytostatic anticancer agents.
Andrew Stone, Catherine Wheeler, Alan Barge

Contemp Clin Trials· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vascular targeting in pancreatic cancer: the novel tubulin-binding agent ZD6126 reveals antitumor activity in primary and metastatic tumor models.
Axel Kleespies, Gudrun Köhl, Michael Friedrich, Anderson J Ryan, Alan Barge

Neoplasia· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer.
Kathy D Miller, Jose Manuel Trigo, Catherine Wheeler, Alan Barge, Jacqui Rowbottom

Clin Cancer Res· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice.
Maksim V Yezhelyev, Gudrun Koehl, Markus Guba, Thomas Brabletz, Karl-Walter Jauch, Alan Barge

Clin Cancer Res· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis